Generalized Pustular Psoriasis in a Child

Kerkhof, P.C.M. van de

doi:10.1159/000249541

Cited by 27 publications

(30 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In all, 21 studies were identified, 46,49,50,52,[61][62][63][64][65][66][67][68][69][70][71][72][73][74][75][76][77] but 5 studies were excluded because of an unclear outcome measure, 46,67-70 9 because they used systemic antipsoriatic combination therapies, 49,50,52,[71][72][73][74][75][76] and one case report because there was no clear diagnosis of psoriasis. 77 Therefore, 6 studies remained: 4 studies were classified as LOE 4 61,63-65 ; two were classified as LOE 5.…”

Section: Retinoidsmentioning

confidence: 99%

“…77 Therefore, 6 studies remained: 4 studies were classified as LOE 4 61,63-65 ; two were classified as LOE 5. 62,66 In 1988 a retrospective review of 10 cases was performed 61 in which etretinate was used at an initial dose of 1 mg/kg/d, with a treatment duration varying from 3 weeks to more than 12 months. All patients with pustular psoriasis (n = 5) achieved complete clearance of lesions; in contrast, the erythrodermic psoriasis subgroup (n = 5) showed a complete clearance of lesions in only two, and an improvement in the remaining 3 cases.…”

Section: Retinoidsmentioning

confidence: 99%

“…Etretinate was also used in two case reports, 62,65 one case series, 63 and one open-label trial. 64 In one case report 62 and one case series 63 1.0 to 1.25 mg/kg/d was administered to patients with pustular psoriasis. All 6 patients had significant regression of erythroderma or even clearance.…”

Section: Retinoidsmentioning

confidence: 99%

“…66 The authors of one case report concerning etretinate did not describe any adverse effects. 62 Conclusion Grade C Number of patients treated with etretinate: 21. Etretinate is an effective treatment for pustular and erythrodermic psoriasis.…”

Section: Retinoidsmentioning

confidence: 99%

See 3 more Smart Citations

Efficacy and safety of treatments for childhood psoriasis: A systematic literature review

Jager

Jong

Kerkhof

et al. 2010

Journal of the American Academy of Dermatology

130

148

View full text Add to dashboard Cite

Section: Retinoidsmentioning

confidence: 99%

Section: Retinoidsmentioning

confidence: 99%

Section: Retinoidsmentioning

confidence: 99%

Section: Retinoidsmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy and safety of treatments for childhood psoriasis: A systematic literature review

Jager

Jong

Kerkhof

et al. 2010

Journal of the American Academy of Dermatology

130

148

View full text Add to dashboard Cite

“…Psoriasis genetik yatkınlığı olan bireylerde, uygun tetikleyici faktörlerin araya girmesi sonucu immün sistemin aktivasyonu, inflamasyonu sınırlayan mekanizmaların bozukluğu ve keratinositlerin hiperreaktivitesi ile ortaya çıkmaktadır 1 . Adipoz doku; olgun adiposit, preadiposit, vasküler, nöral ve immun hücrelerden oluşan metabolik olarak aktif bir dokudur.…”

Section: Gi Riflunclassified

Kronik Plak Tip Psoriasiste TNF-α, IL-6 ve Resistin Seviyeleri

...

2012

Turkderm

View full text Add to dashboard Cite

ÖzetAmaç: Psoriasis kronik, tekrarlayıcı, inflamatuvar bir deri hastalığıdır. Etyolojisi ve patogenezi günümüzde tam olarak aydınlatılamamıştır. Obezite psoriasis için önemli bir risk faktörüdür ve vücut kitle indeksi hastalık şiddetiyle korelasyon gösterir. Son yıllarda psoriasisin adipoz doku sitokinleri ile ilişkisi bildirilmiştir. Bu nedenle biz de bu çalışmada psoriasisli hastalarda, adipoz doku sitokinleri olan TNF-α, IL-6 ve resistin gibi adipokinlerin düzeylerini belirlemeyi ve hastalık şiddetiyle ilişkisini değerlendirmeyi amaçladık. Gereç ve Yöntem: Çalışmamız Ocak-Şubat 2010 tarihleri arasında Dermatoloji polikliniğine başvuran 40 psoriasis hastasını kapsamaktadır. Bu hastalar ile birlikte yaş, cinsiyet, vücut kitle indeksi istatistiksel fark oluşturmayan 40 sağlıklı birey de kontrol grubu olarak değerlendirilmiştir. Psoriasis tanısı konulan hastalarda ve kontrol grubunda TNF-α, IL-6 ve resistin seviyeleri ELİSA yöntemi kullanılarak ölçüldü. Gruplar arası farkın değerlendirilmesi t testi ve Mann-Whitney U testi kullanılarak yapıldı. Bulgular: Hasta grubunun serum TNF-α, IL-6, resistin seviyeleri kontrol grubuyla karşılaştırıldığında TNF-α, IL-6 ve resistin seviyeleri hasta grubunda istatistiksel olarak anlamlı derecede yüksek saptandı. Psoriasis alan şiddet indeksi (PAŞİ) skoru ile IL-6, resistin arasında istatistiksel anlamlılık tespit edildi. Hastaların TNF-α, IL-6 ve resistin seviyeleriyle vücut kitle indeksleri arasında istatistiksel anlamlılık olmadığı görüldü. Sonuç: Bulgularımız TNF-α, IL-6 ve resistin'in psoriasis etyopatogenezinde rol aldığını, IL-6 ve resistin'in hastalık şiddeti ile ilgili belirteçler olabileceğini düşündürmektedir. Ayrıca çalışmamız söz konusu sitokinlerin psorisis hastalarında adipoz doku artışından bağımsız olarak yüksek olduğu görüşünü de desteklemektedir. Bununla birlikte konunun daha geniş çalışmalarla desteklenmesi gerekmektedir. (Türk derm 2012; 46: 138-42) Anah tar Ke li me ler: Psoriasis, TNF-α, IL-6, resistin Sum maryBackground and Design: Psoriasis is a chronic recurrent inflammatory disease of the skin. Despite previous extensive studies, etiology is still unclear. Obesity is a significant risk factor for psoriasis and body mass index (BMI) correlates with the disease severity. In recent years, the relationship between psoriasis and adipose tissue cytokines has been reported. Therefore, in this study, we aimed to determine the levels of adipose tissue cytokines TNF-α, IL-6 and resistin in psoriasis patients and to evaluate their relation with disease severity. Material and Methods: Our study was performed between January 2010 and February 2010 on a total of 40 patients who were admitted to Abant Izzet Baysal University, Medical School Clinic of Dermatology with complaints of psoriasis. Additionally, forty healthy individuals whose age, gender and BMI did not differ from the patients' ones formed the control group. TNF-α, IL-6, and resistin levels were measured in both the patients diagnosed with psoriasis and the control group using ELISA methods. The ttest a...

show abstract

Etretinate Therapy for Generalized Pustular Psoriasis in Children

Shelnitz¹

1987

Arch Dermatol

View full text Add to dashboard Cite

Two children, 19 months of age, were independently treated with a compassionate protocol of etretinate therapy for recalcitrant, debilitating pustular psoriasis. Laboratory test results, roentgenograms of the spine, and bone age were periodically monitored. Over a 31/2-year period of intermittent treatment with a maximum dosage of 1.5 mg/kg/d, both children showed remarkable improvement with no apparent drug effect on growth and development. Side effects included xerosis, skin fragility and transient, minimal elevations of aspartate aminotransferase, lactic dehydrogenase, and triglyceride levels. Etretinate therapy may prove to be a viable treatment option for the child with intractable pustular psoriasis that seriously impairs quality of life.

show abstract

Generalized Pustular Psoriasis in a Child

Cited by 27 publications

References 5 publications

Efficacy and safety of treatments for childhood psoriasis: A systematic literature review

Efficacy and safety of treatments for childhood psoriasis: A systematic literature review

Kronik Plak Tip Psoriasiste TNF-α, IL-6 ve Resistin Seviyeleri

Etretinate Therapy for Generalized Pustular Psoriasis in Children

Contact Info

Product

Resources

About